🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs

Molecules(2022)10.3390/molecules27123678Source: DataRank Database

Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs is a research paper published in Molecules (2022). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)OA: goldTopics (15)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Kendra Springs,Jordan E. Morningstar ORCID,Catherine M. Mills ORCID,Andrew Stoddard,Lilong Guo ORCID

Live enrichment

PubMed:35744803 PMC:PMC9227314

National Institutes of Health (NIH)

Grant: R01-HL131546

National Institutes of Health (NIH)

Grant: R01-149696

National Institutes of Health (NIH)

Grant: R01-HL122906

National Institutes of Health (NIH)

Grant: R01-HL162913

National Institutes of Health (NIH)

Grant: P30-1034444

National Institutes of Health (NIH)

Grant: F31-HL158243

National Institutes of Health (NIH)

Grant: T32-HL007260

National Institutes of Health (NIH)

Grant: 19TPA34850095

National Institutes of Health (NIH)

Grant: 20SRG35540029

National Institutes of Health (NIH)

Grant: 19TPA34900016

National Institutes of Health (NIH)

Grant: TD1612

NHLBI NIH HHS

Grant: R01 HL149696

NHLBI NIH HHS

Grant: R01 HL131546

NHLBI NIH HHS

Grant: R01 HL162913

NHLBI NIH HHS

Grant: T32 HL007260

NHLBI NIH HHS

Grant: F31 HL158243

NHLBI NIH HHS

Grant: R01 HL122906

National Institutes of Health

Grant: 1R01HL149696-01A1

Dzip1 and Mitral Valve Prolapse

National Institutes of Health

Grant: 5F31HL158243-03

Targeting Mek/Erk Signaling in the Treatment of Mitral Valve Prolapse

National Institutes of Health

Grant: 1R01HL122906-01A1

Mechanisms of DMP Development and Atrioventricular Septation

National Institutes of Health

Grant: 5T32HL007260-18

TRAINING TO IMPROVE CARDIOVASCULAR DRUG THERAPY

National Institutes of Health

Grant: 1R01HL131546-01A1

Cilia and Valvular Heart Disease

National Institutes of Health

Grant: 5R01HL162913-04

Role of the Epicardium in Valve Development and Valve Disease

goldLicense: cc-by

publisherhttps://www.mdpi.com/1420-3049/27/12/3678/pdf?version=1654666294

publisherhttps://www.mdpi.com/1420-3049/27/12/3678/pdf

repositoryhttps://dx.doi.org/10.3390/molecules27123678

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9227314

Europe_PMChttps://europepmc.org/articles/PMC9227314

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Antineoplastic AgentsDrug Discovery

Keywords

ToxicityCancerdrug discoveryDrug DevelopmentMachine LearningMek1CommunicationOrganic chemistryAntineoplastic AgentsQD241-441

Sustainable Development Goals

SDG 3: 3. Good health